Samsung Pharmaceutical discloses corporate governance report: only 4 out of 15 core indicators met, lack of shareholder return and CEO succession policy highlights need for governance improvement
Only 4 out of 15 core governance indicators (26.7%) are met, indicating overall weak governance: shareholder meeting notice given only 2 weeks prior instead of 4, lack of dividend policy and CEO succession plan, absence of risk management internal control policy, all-male board composition, etc.
Largest shareholder is Gemvax & Kael (10.46%), while minority shareholders hold 89.54% but no separate communication events or shareholder proposals occurred during the period.
FY2025 consolidated revenue 46.07B KRW, operating loss 18.07B KRW, net profit 11.55B KRW (turnaround from prior year loss of 14.09B KRW), but no dividends or share buybacks due to insufficient distributable profits; no shareholder returns for past 3 years.
Issued 32nd unsecured private convertible bond of 26.9B KRW in August 2025 (conversion price 1,591 won, current price 1,515 won). Immediate dilution limited due to stock price below conversion price, but potential dilution of up to ~16.9M shares (~18% of outstanding) if conversion occurs at higher prices.
Board consists of 4 inside directors and 2 outside directors, all male. Outside director ratio 33.3%, but board chair is an inside director. No board committees established.
[AI Summary]Despite net profit turnaround, Samsung Pharmaceutical's governance remains weak with only 26.7% compliance rate, no shareholder return policy, and no CEO succession plan, limiting long-term value creation; the outstanding convertible bond's potential dilution and weak internal controls warrant continuous monitoring for investors.